Current Headlines

  1. Startup's Biosensor Makes Drug Development And Manufacturing Cheaper 6/15/2025

    In the biotech and pharmaceutical industries, ELISA tests provide critical quality control during drug development and manufacturing.

  2. Samsung Biologics Launches Drug Screening Services, Samsung Organoids 6/15/2025

    Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development.

  3. Mitsubishi Research Institute And Astellas Announce Collaboration To Support Pharma Startups In Japan 6/13/2025

    Mitsubishi Research Institute, Inc. ("MRI") and Astellas Pharma Inc. ("Astellas") today announced that they have agreed on a memorandum of understanding to provide drug-discovery startups in Japan with support in their efforts to go global.

  4. Salipro Biotech And Daewoong Pharmaceutical Announce Collaboration Agreement To Advance Development Of Novel Therapeutics 6/12/2025

    Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters).

  5. Silicogenix Partners With BioDuro To Accelerate Novel Drug Discovery For Complex Diseases 6/10/2025

    Today, Silicogenix (SGX), the pioneer of fit-for-purpose small molecule design technology that empowers polypharmacology and non-traditional drug development, announced a groundbreaking partnership with BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO).

  6. China's Center For Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application For Marketing Authorization Of Pimicotinib For Treatment Of Tenosynovial Giant Cell Tumor 6/10/2025

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment.

  7. Emulate Launches AVA Emulation System To Accelerate Drug Development With First-Of-Its-Kind High-Throughput Organ-Chip Platform 6/10/2025

    Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run.

  8. AlphaMeld Corporation And VedTechBio Forge Strategic AI-Powered Drug Discovery Alliance To Transform Metabolic And Liver Disease Therapeutics 6/10/2025

    AlphaMeld Corporation, a global frontrunner in AI-powered drug discovery, and VedTechBio Research Pvt. Ltd., an emerging biopharma technology innovator specializing in translational research and program execution, today announced a multi-program strategic partnership to accelerate the development of novel therapies for metabolic and liver diseases, including obesity and rare hepatic disorders.

  9. CN Bio Introduces Cross-Species DILI Services To Enhance In Vitro To In Vivo Extrapolation During Preclinical Drug Development 6/10/2025

    CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS).

  10. Bexorg Announces Research Collaboration With Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform To Enhance CNS Drug Development 6/10/2025

    Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders.